
First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis
This week, Mycovia Pharmaceuticals announced it has enrolled its first participant for its phase 2 PLATFORM-CM clinical trial evaluating oteseconazole for cryptococcal meningitis.1 This is an open-label randomized trial with single or potentially multiple …